Assessment Of Rapid Antidepressant Effect Of Oral Ketamine As An Adjuvant In Severe Depression

ASSESSMENTENT OF RAPID ANTIDEPRESSANT EFFECT OT ORAL KETAMINE AS AN ADJUVANT IN SEVERE DEPRESSION -A SINGLE BLIND RANDOMISED CONTROLLED TRIAL - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/03/081539

Enrollment

Registered

2025-03-03

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: PCS-

Interventions

Intervention1: oral ketamine: ketamine given at 2mg/kg mixed in 100ml of water over a period of 30 minutes Given orally on day 1,3,5,7,9 (total 5 doses given on alternate days) Control Intervention1:

Eligibility

Inclusion criteria

Inclusion criteria: Patient aged above 18 yrs of age Patients who have given written informed consent Patient with diagnosis of 1. SINGLE EPISODE DEPRESSIVE DISORDER, severe, without psychotic disorder 2. Recurrent Depressive Disorder, current episode severe without psychotic disorder

Exclusion criteria

Exclusion criteria: Bipolar depression Severe depression with psychotic symptoms Pregnant and lactating women Substance abuse (excluding nicotine dependence) Have received ECT in past 2 months Did not give consent for the same

Design outcomes

Primary

Measure	Time frame
To assess the rapid anti-depressive effect of oral ketamine as an adjuvant antidepressant in severe depressionTimepoint: 1 yr	—

Secondary

Measure	Time frame
To assess the rapid anti suicidal effect of oral ketamine when given as an adjuvantTimepoint: 1 yr	—

Countries

India

Contacts

Public ContactDR SAUMYA MISHRA

JNMC MEDICAL COLLEGE,KLE

DRCHATE@GMAIL.COM9793888829

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026